PRVB News and Press, Provention Bio Inc. From 05/26/21

Agilent price target raised by analysts after better than expected Q2 resultsSeveral firms have lifted the price target for Agilent Technologies (A) after the company raised the fiscal 2021 guidance and reported better-than-expected Q2 FY21 earnings. Agilent has added ~5.1% in ...

Gainers: Flanigan's Enterprises (BDL) +73%.Pieris Pharmaceuticals (PIRS) +48%.RYB Education (RYB) +27%.uCloudlink (UCL) +24%.Friedman Industries (FRD) +23%.Taiwan Liposome (TLC) +19%.Provention Bio (PRVB) +19%.The Joint (JYNT) +18%.New Oriental Education & Technology (EDU) +18%....

Shares of Provention Bio (NASDAQ: PRVB) were soaring 21.6% as of 10:56 a.m. EDT on Tuesday. The big jump came after the U.S. Food and Drug Administration (FDA) released briefing documents in advance of an advisory committee meeting scheduled for May 27. This advisory committee will ...

Provention Bio Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab PR Newswire RED BANK, N.J. , May 25, 2021 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and ...

Provention Bio (PRVB) has gained ~36.7% in the pre-market after the FDA published the briefing documents for teplizumab ahead of an Advisory Committee meeting scheduled for May 27.The company seeks approval for teplizumab in the delay of progression to clinical type 1 diab...

Gainers: [[VRNA]] +31.8%. [[PDD]] +6.1%. [[SHYF]] +4.6%. [[OCX]] +3.9%. [[VERI]] +3.9%.Losers: [[IOVA]] -11.1%. [[PRPL]] -4.0%. [[PRVB]] -3.4%. [[OZON]] -3.3%. [[ACCD]] -3.0%. For further details see: VRNA, PDD, IOVA and PRVB among after-hours movers

Provention Bio, Inc. (PRVB) Q1 2021 Earnings Conference Call May 06, 2021, 08:00 AM ET Company Participants Robert Doody - VP of IR Ashleigh Palmer - CEO, Co-Founder Andrew Drechsler - CFO Francisco Leon - CSO, Co-Founder Jason Hoitt - CCO Conference Call Participants Alethia Young - Cantor G...

Image source: The Motley Fool. Provention Bio, Inc (NASDAQ: PRVB) Q1 2021 Earnings Call May 7, 2021 , 8:00 p.m. ET Operator Continue reading For further details see: Provention Bio, Inc (PRVB) Q1 2021 Earnings Call Transcript

Provention Bio (PRVB) shares sank in reaction to deficiencies identified by the FDA in connection with its marketing application for teplizumab in the delay or prevention of clinical type 1 diabetes.Following the company’s Q1 2021 results, Cantor Fitzgerald analyst Alethia Young h...

Provention Bio (PRVB): Q1 GAAP EPS of -$0.52 misses by $0.05.As of March 31, 2021, Provention Bio had cash and cash equivalents and marketable securities of $207.2 million.Press Release For further details see: Provention Bio EPS misses by $0.05